Straumann Holding AG (STMN) AI Stock Analysis

• Market Cap: CHF14.30B
• Dividend Yield: 1.06%
• Average Volume (3M): 432.72K
• Price to Earnings (P/E): 36.4
• Beta (1Y): 1.36
• Revenue Growth: 4.49%
• EPS Growth: 45.08%
• Country: CH
• Employees: 11,342
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.66
• Shares Outstanding: 159,455,250
• 10 Day Avg. Volume: 467,691
• 30 Day Avg. Volume: 432,724
• PEG Ratio: 0.80
• Price to Book (P/B): 8.93
• Price to Sales (P/S): 7.27
• P/FCF Ratio: 57.71
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF130.10
• Price Target Upside: 43.41% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 11

• Rating: 71 Outperform
• Price Target: CHF102.00 ▲(12.43% Upside)

Straumann Holding AG's strong financial performance and positive earnings call are the primary drivers of its stock score. However, bearish technical indicators and a high valuation limit the overall score. The company's strategic initiatives and market expansions provide a solid foundation for future growth, but investors should be cautious of current market conditions.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective business strategies, supporting long-term financial stability.

Product Innovation

Successful product launches like iEXCEL enhance competitive positioning and drive market share gains, ensuring future growth.

Regulatory Approval in China

Gaining regulatory approval in China strengthens market presence in a key region, supporting strategic growth and revenue potential.

Negative Factors

Currency Headwinds

Currency fluctuations can significantly impact revenue and profitability, posing a risk to financial performance and strategic planning.

Tariffs and Inflation

Tariffs and inflationary pressures can increase costs and affect pricing strategies, potentially impacting margins and market competitiveness.

Orthodontics Segment Challenges

Challenges in the orthodontics segment can hinder growth in key markets, affecting overall revenue and strategic objectives.

Straumann Holding AG Business Overview & Revenue Model

Company Description

Straumann Holding AG provides tooth replacement and orthodontic solutions worldwide. It researches, develops, manufactures, and supplies dental implants, instruments, CADCAM prosthetics, orthodontic aligners, biomaterials, and digital solutions for use in tooth correction, replacement, and restoration, as well as to prevent tooth loss. The company offers dental implant systems for tissue and bone level; titanium, titanium alloy, ceramic, and mini dental implant systems; and guided and non-guided surgical instruments, as well as implant-borne prosthetics. It provides ceramic healing and screw retained abutments; intraoral scanning solutions; 3D printers; milling machines; and prevention products. In addition, it offers biomaterials, bone substitutes, membranes, biologics, and soft tissue management and oral healing products; digital solutions for dental labs, dentists, and centralized milling centers, as well as materials, third party systems, and guided surgery; surgical instruments comprising surgical and modular cassettes, guided instruments, implant maintenance products, bone block fixation sets, bonerings, titanium pin sets, and other cassettes; and edentulous, pro arch fixed, prosthetic, and mini implant solutions for edentulous patients. Further, it provides esthetic restorations that include ceramic implant monotypes, ceramic implants, abutments, biologics, and other solutions; and Emdogain for wound healing. Further, it offers systems Clear Correct aligners; and training and education services to its customers. The company provides its products to general dentists, specialists, and dental technicians and laboratories, as well as corporate customers, such as distributors, hospitals, universities, and dental service organizations in approximately 100 countries through a network of distribution subsidiaries and partners. Straumann Holding AG was founded in 1954 and is headquartered in Basel, Switzerland.

How the Company Makes Money

Straumann generates revenue primarily through the sale of dental implants and related products, including prosthetics and biomaterials. The company operates a direct sales model as well as through a network of distributors and partners, allowing it to reach a global market. Key revenue streams include the sale of dental implant systems, digital dentistry solutions, and regenerative materials. Additionally, Straumann has established strategic partnerships and collaborations with dental professionals, research institutions, and other industry players to enhance its product offerings and market reach. The company's focus on innovation, evidenced by significant investment in research and development, further contributes to its ability to capture market share and drive revenue growth.

Straumann Holding AG Financial Statement Overview

Summary

Straumann Holding AG shows strong financial performance with consistent revenue growth and a solid balance sheet. However, rising operational costs and liabilities are areas to monitor.

Income Statement

Straumann Holding AG has demonstrated consistent revenue growth with a solid increase from 2023 to 2024. Gross Profit Margin is strong, indicating effective cost management. However, there is a slight decline in EBIT and EBITDA margins, suggesting rising operating costs or increased competition.

Balance Sheet

The company's balance sheet is stable with a moderate Debt-to-Equity ratio, reflecting balanced leverage. The Return on Equity is healthy, indicating efficient use of equity. The Equity Ratio is solid, showing a strong financial position, although the increase in total liabilities warrants monitoring.

Cash Flow

The cash flow is robust with a stable Free Cash Flow, reflecting the company's good cash generation capacity. There is a slight decline in Operating Cash Flow, which could be a sign of higher operational expenses. The Free Cash Flow to Net Income ratio is favorable, indicating efficient cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.58B	2.50B	2.41B	2.32B	2.02B	1.43B
Gross Profit	1.83B	1.78B	1.79B	1.70B	1.53B	1.03B
EBITDA	850.33M	726.15M	685.07M	685.37M	591.48M	230.45M
Net Income	392.72M	388.32M	246.07M	434.79M	396.08M	91.28M
Balance Sheet
Total Assets	3.51B	3.62B	3.40B	3.45B	3.05B	2.62B
Cash, Cash Equivalents and Short-Term Investments	246.53M	383.07M	413.54M	697.11M	881.50M	632.49M
Total Debt	411.27M	413.89M	412.35M	705.20M	711.66M	731.66M
Total Liabilities	1.45B	1.58B	1.56B	1.60B	1.55B	1.41B
Stockholders Equity	2.06B	2.04B	1.84B	1.85B	1.50B	1.20B
Cash Flow
Free Cash Flow	351.32M	315.62M	316.61M	220.94M	440.97M	295.34M
Operating Cash Flow	500.77M	483.39M	503.95M	416.38M	561.94M	377.41M
Investing Cash Flow	-392.95M	-352.62M	-349.33M	-449.84M	-185.20M	-145.64M
Financing Cash Flow	-180.68M	-169.06M	-424.40M	-140.35M	-122.90M	153.33M

Straumann Holding AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 90.72
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:STMN, the sentiment is Negative. The current price of 90.72 is below the 20-day moving average (MA) of 92.72, below the 50-day MA of 97.96, and below the 200-day MA of 108.55, indicating a bearish trend. The MACD of -2.00 indicates Negative momentum. The RSI at 38.10 is Neutral, neither overbought nor oversold. The STOCH value of 20.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:STMN.

Straumann Holding AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SOON	73 Outperform	13.37B	25.62	20.28%	1.90%	6.58%	-10.02%
STMN	71 Outperform	CHF14.30B	36.40		1.06%	4.49%	45.08%
GALD	71 Outperform	33.64B	102.48	2.97%	0.11%	6.22%	0.00%
SKAN	67 Neutral	1.28B	79.22	19.78%	0.71%	-3.45%	-49.82%
ALC	66 Neutral	30.79B	32.54	4.72%	0.46%	1.60%	-4.40%
MED	61 Neutral	1.22B	-2,288.27	1.31%	―	7.29%	-112.70%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Straumann Holding AG Corporate Events

Straumann Raises CHF 250 Million Through Successful Bond Issuance

Straumann Holding AG has successfully raised CHF 250 million through a three-year bond issuance, with the proceeds intended for refinancing an existing bond and general corporate purposes. This strategic financial move, supported by UBS AG and Zürcher Kantonalbank, is expected to bolster Straumann’s operational capabilities and maintain its strong market position in the dental solutions industry.

The most recent analyst rating on (CH:STMN) stock is a Hold with a CHF113.00 price target. To see the full list of analyst forecasts on Straumann Holding AG stock, see the CH:STMN Stock Forecast page.